Human diploid MRC-5 cells exhibit several critical properties of human umbilical cord-derived mesenchymal stem cells

Vaccine

Volumn 32, Issue 50, 2014, Pages 6820-6827

  Zhang, Kehua ^a   Na, Tao ^a   Wang, Lin ^b   Gao, Qiang ^b   Yin, Weidong ^b   Wang, Junzhi ^a   Yuan, Bao Zhu ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b Sinovac Biotech Co Ltd   (China)

Author keywords

Cell substrate; Human diploid cell; Mesenchymal stem cell; MRC 5; Vaccine production

Indexed keywords

CELL SURFACE MARKER; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; VIRUS VACCINE; BIOLOGICAL MARKER; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; MEMBRANE PROTEIN;

A549 CELL LINE; ADIPOCYTE; ARTICLE; CARCINOGEN TESTING; CARTILAGE CELL; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIPLOIDY; ENTEROVIRUS 71; ENZYME ACTIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFECTION SENSITIVITY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MOUSE; MRC 5 CELL; NONHUMAN; OSTEOCYTE; PROTEIN EXPRESSION; QUALITY CONTROL; REGULATORY T LYMPHOCYTE; RUBELLA VIRUS; UMBILICAL CORD; UMBILICAL CORD DERIVED MESENCHYMAL STEM CELL; VACCINE PRODUCTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; BIOSYNTHESIS; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; GENE EXPRESSION; IMMUNOLOGICAL TOLERANCE; MESENCHYMAL STROMA CELL; PHYSIOLOGY; T LYMPHOCYTE;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; DIPLOIDY; GENE EXPRESSION; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MEMBRANE PROTEINS; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; UMBILICAL CORD;

EID: 84909638337     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.071     Document Type: Article

References (29)

1. Fletcher M.A., Hessel L., Plotkin S.A. Human diploid cell strains (HDCS) viral vaccines. Dev Biol Stand 1998, 93:97-107.
2. Jacobs J.P. The status of human diploid cell strain MRC-5 as an approved substrate for the production of viral vaccines. J Biol Stand 1976, 4:97-99.
3. Jacobs J.P., Jones C.M., Baille J.P. Characteristics of a human diploid cell designated MRC-5. Nature 1970, 227:168-170.
4. Mann G.F., de Mucha J. Replication of poliovirus (LSc 2 ab) in perfused cultures of MRC-5 diploid cells. Dev Biol Stand 1976, 37:255-258.
5. Alirezaie B., Taqavian M., Aghaiypour K., Esna-Ashari F., Shafyi A. Phenotypic and genomic analysis of serotype 3 Sabin poliovirus vaccine produced in MRC-5 cell substrate. J Med Virol 2011, 83:897-903.
6. Thornton B., McEntee I.D., Griffiths B. Production of herpes simplex virus from MRC-5 cells grown in a glass bead culture system. Dev Biol Stand 1985, 60:475-481.
7. Mirchamsy H., Shafyi A., Bahrami S., Kamali M., Nazari P. Use of human diploid cell MRC-5, for production of measles and rubella virus vaccines. Dev Biol Stand 1976, 37:297-300.
8. Pellegrini V., Fineschi N., Matteucci G., Marsili I., Nencioni L., Puddu M., et al. Preparation and immunogenicity of an inactivated hepatitis A vaccine. Vaccine 1993, 11:383-387.
9. Shinohara M., Uchida K., Shimada S., Segawa Y., Hirose Y. The usefulness of human lung embryonal fibroblast cells (MRC-5) for isolation of enteroviruses and adenoviruses. Kansenshogaku zasshi 2002, 76:432-438.
10. Sensebe L., Krampera M., Schrezenmeier H., Bourin P., Giordano R. Mesenchymal stem cells for clinical application. Vox Sanguinis 2010, 98:93-107.
11. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
12. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
13. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
14. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
15. Liu Y., Mu R., Wang S., Long L., Liu X., Li R., et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R210.
16. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011, 10:649-656.
17. Anzalone R., Lo Iacono M., Loria T., Di Stefano A., Giannuzzi P., Farina F., et al. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev 2011, 7:342-363.
18. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
19. Ren G., Su J., Zhang L., Zhao X., Ling W., L'Huillie A., et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009, 27:1954-1962.
20. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
21. Jo C.H., Kim O.S., Park E.Y., Kim B.J., Lee J.H., Kang S.B., et al. Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion. Cell Tissue Res 2008, 334:423-433.
22. Choumerianou D.M., Dimitriou H., Perdikogianni C., Martimianaki G., Riminucci M., Kalmanti M. Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow. Cell Prolif 2008, 41:909-922.
23. Liang X.J., Chen X.J., Yang D.H., Huang S.M., Sun G.D., Chen Y.P. Differentiation of human umbilical cord mesenchymal stem cells into hepatocyte-like cells by hTERT gene transfection in vitro. Cell Biol Int 2012, 36:215-221.
24. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67:9142-9149.
25. Parish C.R., Glidden M.H., Quah B.J., Warren H.S. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr Protoc Immunol 2009, Chapter 4, Unit 4.9.
26. Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Human Gene Ther 2011, 22:19-26.
27. Boroujeni M.E., Gowda P., Johnson J., Rao J., Saremy S. The proliferation and differentiation capacity of bone marrow derived-human mesenchymal stem cells in early and late doubling. Asian J Biochem 2012, 7:27-36.
28. Chen G., Yue A., Ruan Z., Yin Y., Wang R., Ren Y., et al. Monitoring the biology stability of human umbilical cord-derived mesenchymal stem cells during long-term culture in serum-free medium. Cell Tissue Bank 2014, Jan 10. [Epub ahead of print].
29. Jones M., Varella-Garcia M., Skokan M., Bryce S., Schowinsky J., Peters R., et al. Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System. Cytotherapy 2013, 15:1323-1339.